US-based healthcare firm Eli Lilly and Company has reported positive results from three Phase III EVOLVE-1, EVOLVE-2 and REGAIN clinical trials of galcanezumab to prevent episodic and chronic migraine.

Galcanezumab is a monoclonal antibody developed to specifically inhibit the activity of calcitonin gene-related peptide (CGRP).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The results from the trials showed that both 120mg and 240mg doses of the drug met the primary endpoint of a statistically significant decrease in the number of migraine headache days per month.

Lilly Bio-Medicines president Christi Shaw said: "The robust results from these three studies bring us one step closer to helping people experience more migraine-free days, an important treatment goal for those living with this serious disease.

"The impact of migraine is underestimated, with people who experience migraine attacks often missing work, family activities or social engagements.

See Also:

"The robust results from these three studies bring us one step closer to helping people experience more migraine-free days, an important treatment goal for those living with this serious disease."

“For patients with as few as one migraine headache day per week, this can mean more than 50 days of lost productivity a year."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

All the three trials were randomised, double-blind, placebo-controlled and assessed the safety and efficacy of subcutaneous galcanezumab.

While EVOLVE-1 and EVOLVE-2 were conducted for a period of six-months, REGAIN included a treatment period of three months.

The trials’ secondary endpoints such as response rates and measures of daily activities were also found to be significantly improved.

The observed safety and tolerability profile was found to be consistent with data from previous trials of the drug.

Lilly intends to submit a biologics licence application to the US Food and Drug Administration (FDA) for galcanezumab in the second half of this year, based on these results.